Head and Neck Squamous
Cell Carcinoma
CAR T-Cell Therapy in
Hematologic Malignancies
TIL Therapy in
Solid Tumors
Melanoma
Non–Small Cell Lung Cancer
Cervical Cancer
Anti-CD19 CAR-T
BCMA-targeted CAR-T
CD22-targeted CAR-T
CD30-targeted CAR-T
Bi-Specific CAR-T target: CD19/CD22
Anti-CD19 CAR-T
ZUMA-1 Trial: Axicabtagene ciloleucel in refractory large B-cell lymphoma¹¹
• Phase I/II study
• Objective response rate: 82%
• Complete response rate: 58%
JULIET trial: Tisagenlecleucel in relapsed/refractory diffuse large
B-cell lymphoma (DLBCL)¹²
• Phase II study
• Objective response rate: 52%
• Complete response rate: 40%
Anti-CD19 CAR T in relapsed B-cell acute lymphoblastic leukemia (ALL)⁴⁶
• Complete response rate: 83%
• Median event-free survival: 6.1 months
Anti-CD19 CAR T in patients with chronic lymphocytic leukemia (CLL) who had previously received ibrutinib⁴⁷
• Objective response rate: 74%
• Complete response rate: 21%
Tisagenlecleucel in children and young adults with relapsed or refractory B-cell ALL¹⁰
• Objective response rate: 81%
• Complete response rate: 60%
BCMA-targeted CAR-T
Phase I trial: bb2121 in relapsed or refractory multiple myeloma⁴⁸
• Objective response rate: 94%
• Complete response rate: 56%
• 6-month progression-free survival: 81%
CD22-targeted CAR-T
B-cell ALL that is naive or resistant to CD19-targeted CAR immunotherapy⁴⁹
• Complete response rate: 57%
CD30-targeted CAR-T
RELY-30 trial: CD30-targeted CAR-T in patients with
Hodgkin lymphoma⁵⁰
• Complete response rate: 75%
Bispecific CAR-T target: CD19/CD22
Phase I trial: Relapsed or refractory B-cell ALL or DLBCL
• Complete response: 3 of 7 patients
• Partial response: 2 of 7 patients
• Stable disease: 2 of 7 patients
Melanoma
Phase II study: Lifileucel (TIL therapy) + pembrolizumab in patients with immune checkpoint-naive advanced melanoma⁵¹
• Objective response rate: 85.7%
• Complete response rate: 42.9%
Phase II study: Lifileucel (TIL therapy) in heavily pretreated advanced melanoma³⁰
• Objective response rate: 36.4%
TIL therapy in heavily pretreated patients with metastatic melanoma⁵²
• Complete response rate: 22%
• 20.4% (19 patients) had ongoing complete regressions beyond 3 years
Cervical Cancer
Phase II study: TILs for treatment of recurrent, metastatic, or persistent cervical carcinoma³¹
• Objective response rate: 44%
Head and Neck Squamous Cell Carcinoma
Phase II study: TIL + pembrolizumab in advanced, recurrent, or metastatic head and neck squamous cell carcinoma³²
• Objective response rate: 44%
Non–Small Cell Lung Cancer
Phase I trial: TIL therapy in metastatic non–small cell cancer after evidence of progression on nivolumab⁵³
• Objective complete response: 15.4% (2/13 patients)
Test ⁰ ¹ ² ³ ⁴ ⁵ ⁶ ⁷ ⁸ ⁹⁸ ⁴⁶
©
™
℠
®
•
Super Script: ⁰ ¹ ² ³ ⁴ ⁵ ⁶ ⁷ ⁸ ⁹®P
Subscript: ₀ ₁ ₂ ₃ ₄ ₅ ₆ ₇ ₈ ₉